###### Strengths and limitations of this study

-   This is a multicentre collaborative study composed of units across the UK which are both transplant centres and referring nephrology units.

-   The sample size will be the largest investigating IPV to date.

-   The study uses a unified method across all participating centres, which will enable meaningful comparison between centres.

-   The study investigates retrospective data and requires a lengthy follow-up period which will lead to some exclusions.

-   There will be minor local variations in the laboratory assay that cannot be corrected for in the IPV calculations.

-   Confounding factors such as geographical bias, repatriation as a cause of lost to follow-up, under-representation of poorly compliant patients who do not attend appointments, frequency of sampling and temporary medications are beyond the scope of this study.

Introduction {#s1}
============

The addition of calcineurin inhibitors (CNIs) as maintenance immunosuppressants has improved renal transplant 1-year survival rates since the 1980s.[@R1] Tacrolimus emerged as a viable alternative to ciclosporin in the 1990s.[@R1] In 2005, a meta-analysis was published on randomised trial data comparing tacrolimus and ciclosporin as primary immunosuppressants in renal transplant, observing a 44% reduction in death-censored graft loss with tacrolimus over ciclosporin.[@R2] In 2007, the Symphony Study reported favourable graft survival and function, and reduced biopsy-proven rejection with low-dose tacrolimus over low-dose ciclosporin, sirolimus or standard-dose tacrolimus.[@R3]

CNIs have a narrow therapeutic index: too little exposure places a transplant recipient at increased risk of acute rejection and donor-specific antibody formation. Too much exposure and a transplant recipient is placed at increased risk of malignancy, infection, nephrotoxicity and unacceptable side effects such as tremor.[@R4]

Trough levels are used as a proxy for oral bioavailability of CNIs and vary both between patients (interpatient variability) and for an individual over time (intrapatient variability, IPV). Between individuals, age, gender, ethnicity, body mass index, genetic polymorphisms in CYP3A5 and CYP3A4, drug interactions, adherence, liver function and lifestyle choices account for the differences. Similarly, IPV is affected by adherence, gastrointestinal metabolism and motility, diarrhoea, food and drug interactions, synchronicity of dose administration and blood test and variability of the laboratory assay.[@R8]

An emerging body of evidence is being established indicating favourable graft function, survival and fewer rejection episodes up to 1 year post-transplant for patients demonstrating low IPV.[@R16] Similarly, high IPV has been associated with poorer outcomes and graft survival.[@R19] Donor age and previous transplants appear to be risk factors for a high IPV.[@R18] However, little data exists on the long-term impact of high IPV and studies have not yet been able to draw conclusions about risk thresholds of variability because of limitations in sample size.

Objectives {#s1a}
----------

-   To establish important baseline data about national and regional trends in IPV

-   To investigate demographic associations and other characteristics for patients in high and low variability groups

-   To establish whether there exists a 'danger' threshold for IPV, above which a patient is deemed at risk of graft loss or dysfunction, so they can then be targeted for intervention prior to organ damage or failure

Outcomes {#s1b}
--------

*Primary outcomes*: Recent 12 months' IPV, IPV months 6--12, change in IPV.

*Secondary outcomes*: Ethnicity, recipient age, change in IPV, previous transplants, DR mismatch, graft function, graft survival, gender.

Confounders {#s1c}
-----------

We acknowledge the potential for confounding factors that are outside the scope of this study to address. These include frequency of tacrolimus level sampling (and the reasons why this might be increased) and conversely under-representation of poorly compliant patients who do not attend appointments. These confounders may be affected by hospital admissions, temporary medication use (such as oral antibiotics) and those patients with a modified tacrolimus target.

Methods and analysis {#s2}
====================

A multicentre transplant audit collaborative (TAC) has been established to conduct a retrospective study examining tacrolimus IPV and renal transplant outcomes. It is the first collaborative of its kind, facilitating the development of this largest study examining IPV to date. TAC is composed of junior doctors with an interest in nephrology and/or transplantation. It is supported by Consultant physicians and surgeons in these fields to undertake research and audit projects related to transplantation. Any UK NHS Trust involved in the aftercare of renal transplant recipients is eligible to register for this study providing they have a transplant or nephrology doctor willing to enrol in the TAC.

Patient selection {#s2a}
-----------------

Patients in receipt of a renal transplant at participating centres between 2009 and 2014 and fulfilling the inclusion criteria will be included in the study ([table 1](#T1){ref-type="table"}). To be enrolled, patients are required to have follow-up spanning at least 2 years in order to determine a threshold IPV above which a renal transplant recipient would be considered at increased risk of graft loss.

###### 

Inclusion/exclusion criteria

  Inclusion criteria                           Exclusion criteria
  -------------------------------------------- ---------------------------------------------------------------------------------
  Age ≥18 years at time of transplant          Age ≤17 years at time of transplant
  A functioning graft\* at 2 years             Failed graft before 2 years
  Renal-only transplant                        Non-renal transplant
  Short-acting tacrolimus preparation          Modified release preparation at any
  Only during study period                     Point during study period
  Tacrolimus as primary immunosuppressant      Other primary immunosuppressant (eg, ciclosporin, sirolimus, other non-steroid)
  Alive minimum 2 years following transplant   Pregnancy at any point during study period
                                               Death prior to 2 years following transplant
                                               Non-standard transplant (ABO or HLA incompatible; requiring desensitisation)
                                               Patients with fewer than four tacrolimus trough levels for T1 and T2

T1, 6--12 months post-transplant; T2, most recent 12 months.

Sample size {#s2b}
-----------

A large sample size is needed to provide meaningful numbers to establish variability risk cut-offs. It is estimated that a minimum of eight UK-based centres will participate in the study. If each centre, on average, supplies data for 200 patients, a minimum dataset of 1600 patients will be achieved.

It is, however, recognised that there will be a significant variation between the numbers of eligible patients available to each centre (tertiary transplant units will naturally have access to larger numbers that referring District General Hospitals). The set number of 200, therefore, is only to be used as a guide and it is recognised that this may not be achievable for smaller, secondary nephrology units. Similarly, we welcome larger numbers from any centre able to do so.

Data collection and information governance {#s2c}
------------------------------------------

TAC has established a standard minimum dataset (see [box 1](#B1){ref-type="boxed-text"}) which each site will use as the basis for data collection. A template database will be provided to a representative of the study team from each NHS Trust participating in the study. This database will be password protected and held on secure local Trust servers. All data should be entered onto this database -- the use of hard copy proformas associated with this audit is discouraged to avoid breaching data protection policies.Box 1Minimum datasetData setDate of transplantRecipient and donor agesGenderEthnicityPrimary renal diagnosisPrevious transplantsMismatch grade (A, B, DR)Type of donoreGFR at the end of T1 and T2Creatinine at 12 months and at the end of T2All tacrolimus trough levels during T1 and T2Urinary protein creatinine ratio at the of end T1 and T2Graft failureDelayed graft functionTacrolimus dosing at month 12 and at the end of T2Other immunosuppression at both T1 and T2:Steroid Y/N;MMF Y/N;Azathioprine Y/NInduction agentDe novo donor-specific antibody status post-transplant and level (mean fluorescence intensity)Biopsy-proven acute rejectionDeath[^1]

The data collection database will be anonymised and will contain no patient identifiable data. Each hospital will be issued with patient study identifiers for all patients included in the study. A separate password-protected spreadsheet of the study identifiers with the corresponding hospital numbers should be securely stored locally by each participating centre for local reference only should there be any difficulties or queries regarding data collection.

The anonymised master database will be compiled by a dedicated, named member of the collaborative. It will be shared with all members of TAC using secure NHS email only (either local Trust email or NHS.net) and will be held on secure, password-protected Trust servers only.

Data collection has been under way since March 2017 and is scheduled for completion in September 2017. A period of data analysis will then follow until December 2017 at which time the results will be disseminated as detailed in the Ethics and Dissemination section below.

Data analysis {#s2d}
-------------

Studies have shown that high IPV is associated with poorer renal transplant outcomes[@R17] but no research group has yet established or described an IPV level at which the risk of such outcomes is significantly increased. With our large sample size, we will be able to stratify our group into quartiles or quintiles based on IPV, enabling us to compare outcomes between the groups.

IPV will be calculated using the mean absolute deviation as described by Shuker *et al*.[@R18] Individual subjects will be stratified into groups based on observed variability during T1. Intergroup comparisons will be made using both univariate and multivariate analyses for the clinically relevant end points including graft loss, graft dysfunction (assessed by eGFR and new onset proteinuria) and biopsy-proven rejection episodes. The univariate predictive value of T1 IPV for these outcomes will be evaluated by receiver operator curve assessment.

Categorical variables will be compared using Χ^2^ and Fisher\'s exact test where appropriate. Continuous variables will be assessed using T test for parametric and Mann-Whitney U test for non-parametric data.

Multivariate analysis will use Cox regression survival analysis to compare event-free survival, corrected for potential confounders including age, gender and ethnicity. Where there is loss to follow-up after the 2-year period, data will be censored according to last known status at the time of last creatinine or tacrolimus level (whichever is the latter).

Permissions and registration {#s2e}
----------------------------

Each participating centre will be expected to complete a site registration form. A named member of TAC from each participating centre will be responsible for gaining all necessary local Trust permissions and study registrations as required by local Research and Development and Audit offices.

Consent will not be sought from patients whose data are used in this study as no additional procedures or information will be required from participants beyond that which would normally take place as part of clinical care. The findings of the study are not expected to impact on individual patient care.
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